Evidence map›Paper›PMID 33258993›Full record

ArticleBasic research in cardiology2020

Tenascin C promotes valvular remodeling in two large animal models of ischemic mitral regurgitation.

Ouafa Hamza, Attila Kiss, Anne-Margarethe Kramer, Sandra Trojanek, Dietmar Abraham, Eylem Acar, Felix Nagel, Verena Eva Tretter, Melitta Kitzwögerer, Bruno K Podesser

Open access · hybridAbstract read
In one paragraph

Article in Basic research in cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. The Role of Tenascin-C in Neuroinflammation and Neuroplasticity.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ouafa HamzaLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.ORCID 0000-0002-3025-7064
Attila KissLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Anne-Margarethe KramerLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Sandra TrojanekCenter for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria.
Dietmar AbrahamCenter for Anatomy and Cell Biology, Medical University of Vienna, Vienna, Austria.
Eylem AcarLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Felix NagelLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Verena Eva TretterDepartment of Anesthesia, General Intensive Care and Pain Therapy, Medical University of Vienna, Vienna, Austria.
Melitta KitzwögererDepartment of Pathology, Karl Landsteiner University, St. Pölten, Austria.
Bruno K PodesserLudwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. bruno.podesser@meduniwien.ac.at.
Medical University of Vienna · ATLudwig Boltzmann Institute for Cardiovascular Research · AT

Funding

Ludwig Boltzmann Institut REM2017-20Medical Scientific Fund of the Mayor of the City of Vienna AP18124BGM
6 · The paper itself

Abstract

Ischemic mitral regurgitation (MR) is a frequent complication of myocardial infarction (MI) characterized by adverse remodeling both at the myocardial and valvular levels. Persistent activation of valvular endothelial cells leads to leaflet fibrosis through endothelial-to-mesenchymal transition (EMT). Tenascin C (TNC), an extracellular matrix glycoprotein involved in cardiovascular remodeling and fibrosis, was also identified in inducing epithelial-to-mesenchymal transition. In this study, we hypothesized that TNC also plays a role in the valvular remodeling observed in ischemic MR by contributing to valvular excess EMT. Moderate ischemic MR was induced by creating a posterior papillary muscle infarct (7 pigs and 7 sheep). Additional animals (7 pigs and 4 sheep) served as controls. Pigs and sheep were sacrificed after 6 weeks and 6 months, respectively. TNC expression was upregulated in the pig and sheep experiments at 6 weeks and 6 months, respectively, and correlated well with leaflet thickness (R = 0.68; p < 0.001 at 6 weeks, R = 0.84; p < 0.001 at 6 months). To confirm the translational potential of our findings, we obtained mitral valves from patients with ischemic cardiomyopathy presenting MR (n = 5). Indeed, TNC was also expressed in the mitral leaflets of these. Furthermore, TNC induced EMT in isolated porcine mitral valve endothelial cells (MVEC). Interestingly, Toll-like receptor 4 (TLR4) inhibition prevented TNC-mediated EMT in MVEC. We identified here for the first time a new contributor to valvular remodeling in ischemic MR, namely TNC, which induced EMT through TLR4. Our findings might set the path for novel therapeutic targets for preventing or limiting ischemic MR.

Indexed as

Epithelial-Mesenchymal TransitionAgedAged, 80 and overAnimalsCells, CulturedDisease Models, AnimalEndothelial CellsFemaleHumansMaleMiddle AgedMitral ValveMitral Valve InsufficiencyMyocardial InfarctionSheep, DomesticSignal TransductionTenascinTNC protein, humanToll-Like Receptor 4Endothelial-to-mesenchymal transitionIschemic mitral regurgitationLeaflet remodelingMyocardial infarctionTenascin C

Identifiers

PMID33258993
PMCPMC7716900
OpenAlexW3109893446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.